Archive for August, 2012

KIT digital (KITD) Implements Management Change, Peter Heiland Appointed CEO

NEW YORK, NY — (Marketwire) — 08/31/12 — The Board of Directors of KIT digital, Inc. (NASDAQ: KITD), a leading video management software and services company, today announced the appointment of K. Peter Heiland, a member of the Board and a significant shareholder, to the position of Chief Executive Officer on an interim basis, succeeding Barak Bar-Cohen. The Board continues its search for a permanent Chief Executive Officer.

“I look forward to working with my colleagues at KIT digital to continue delivering value to our leading broadband media customers around the world,” said Mr. Heiland. “When I joined the Board earlier this month, I did so with the objectives of helping to bring the strategic transaction process to a resolution and helping to ensure that KIT digital was positioned for long-term profitable growth. Together with the Board, newly appointed CFO Fabrice Hamaide, and the rest of KIT digital’s outstanding team of industry-leading professionals, achieving these objectives remains our top priority.”

Through various entities, Mr. Heiland owns approximately 8% of the outstanding shares of KIT digital. Mr. Heiland is a Managing Director of JEC Capital Partners, LLC, a technology focused investment firm that was founded in 2009. Prior to founding JEC Capital Partners, he spent 22 years operating a global technology company. He has also served on boards of public and private technology companies, including GSI Group and Integrated Dynamics Engineering.

Speaking on behalf of the Board, non-executive Chairman Bill Russell said, “We believe that Peter is the right person to step in and, with ongoing Board input, help make key decisions that serve the common interests of our shareholders, customers, and employees. As a Board, we have been impressed with Peter’s management skills, his leadership and his track record of building and operating profitable technology companies as a CEO and as a board member.”

Russell continued, “We are also grateful to Barak Bar-Cohen for his service to the company over the past four years. His leadership as an officer has been imperative in resetting the strategic course for KIT digital, and we look forward to his continued involvement as a director.”

KIT digital on Wednesday announced that the company was selected to design, build, and manage a new, state-of-the-art digital cable television distribution platform for India in a new 5-year engagement valued at $15 million contract that includes 5 years of ongoing system maintenance. The company was also named the leader in the content management systems market for large IPTV operators by ABI Research, a market intelligence company specializing in global technology markets.

The entire Board will continue to manage the company’s ongoing strategic process to a conclusion.

About KIT digital, Inc.
KIT digital (NASDAQ: KITD) is a leading video management software and services company. Cosmos and Cloud, the company’s video asset management systems, enable leading broadband media companies to produce, manage and deliver multiscreen socially-enabled video experiences to audiences wherever they are. KIT digital services nearly 2,500 clients in 50+ countries including some of the world’s biggest brands, such as Airbus, The Associated Press, AT&T, BBC, BSkyB, Disney-ABC, Google, HP, Mediaset, MTV, News Corp, RCS Media Group, Sky Deutschland, Sky Italia, Telecom Argentina, Telecom Italia, Telefonica O2, Universal Studios, Verizon, Vodafone and Volkswagen. KIT digital maintains headquarters in New York City and offices in more than a dozen countries around the world. Visit the company at www.kitd.com or follow on Twitter at www.twitter.com/KITdigital.

This press release contains certain “forward-looking statements” related KIT digital, Inc., which can be identified by the use of forward-looking terminology, such as “objective,” “seek, ” “achieve,” “believe,” “continue,” and the like and variations of such words or similar expressions, but their absence does not mean that the statement is not forward- looking. Such forward-looking statements include, but not limited to, statements regarding anticipated value of newly signed contracts, comments regarding the conclusion of our strategic process and statements regarding the long-term positioning of the Company and statements made concerning our potential. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development and commercialization, integration of acquired businesses, the ability to obtain or maintain patent and other proprietary intellectual property protection, market acceptance, future capital requirements, regulatory actions or delays, competition in general and other factors that may cause actual results to be materially different from those described herein. Certain of these risks and uncertainties are or will be described in greater detail in our public filings with the U.S. Securities and Exchange Commission. Except as required by U.S. federal securities laws, KIT digital is not under obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

Add to Digg Bookmark with del.icio.us Add to Newsvine

KIT digital Media Contact:
Daniel Goodfellow
SVP, Global Marketing and Communications
Tel. +1-917-513-6081
Email Contact

KIT digital Investor Contact:
Murray Arenson
Managing Director, Financial Strategy
Tel. +1-646-553-4900
Email Contact

Friday, August 31st, 2012 Uncategorized Comments Off on KIT digital (KITD) Implements Management Change, Peter Heiland Appointed CEO

Brigus Gold (BRD) Completes Sale of Calais Notes

Brigus Gold Corp. (NYSE MKT: BRD; TSX: BRD) (“Brigus” or the “Company”) has received the final payment of USD $4.5 million from New West Capital to complete the sale of the Calais Notes (“Notes”) as announced on May 7, 2012 for total proceeds of USD $6 million.

Brigus acquired the Notes as consideration when the Company sold a non-core asset in 2010 and were originally valued and recorded at $3.4 million. When combining the $1.2 million that was repaid in 2011 from Calais Resources Inc. with the proceeds from this sale, the Company received a total of $7.2 million in cash for the Notes.

About Brigus Gold

Brigus is a growing gold producer committed to maximizing shareholder value through a strategy of efficient production, targeted exploration and select acquisitions. The Company operates the wholly owned Black Fox Mine and Mill in the Timmins Gold District of Ontario, Canada. The Black Fox Complex encompasses the Black Fox Mine and adjoining properties in the Township of Black River‐Matheson, Ontario, Canada. Brigus is also advancing the Goldfields Project located near Uranium City, Saskatchewan, Canada, which hosts the Box and Athona gold deposits. In Mexico, Brigus has granted Cangold Limited the option to acquire a 75% interest in the Company’s Ixhuatan Project located in the state of Chiapas. In the Dominican Republic, Brigus has signed an agreement to sell its remaining interests in three mineral exploration projects.

Cautionary and Forward‐Looking Statements

Statements contained in this news release, which are not historical facts, are forward‐looking statements that involve risk, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward‐looking statements. All statements regarding the ability of the Company to achieve its production, total cash costs, steady state annual production and mining rate estimates; estimated average gold grades for the open pit and underground operations; increase in gold production; increase in profitability; exploration drill results and resource additions, are forward‐looking statements and estimates that involve various risks and uncertainties. This forward‐ looking statements include, or may be based upon, estimates, forecasts, and statements as to management’s expectations with respect to, among other things, the outcome of legal proceedings, the issue of permits, the size and quality of the Company’s mineral resources, progress in development of mineral properties, future production and sales volumes, capital and mine production costs, demand and market outlook for metals, future metal prices and treatment and refining charges, and the financial results of the Company. Important factors that could cause actual results to differ materially from these forward‐looking statements include environmental risks and other factors disclosed under the heading “Risk Factors” in Brigus’ most recent Annual Information Form and Management Discussion and Analysis filed under the Company’s name at www.sedar.com and annual report on Form 40F filed with the United States Securities and Exchange Commission at www.sec.gov as well as elsewhere in Brigus’ documents filed from time to time with the Toronto Stock Exchange, the NYSE Amex Equities, the United States Securities and Exchange Commission and other regulatory authorities. All forward‐looking statements included in this news release are based on information available to the Company on the date hereof. The Company assumes no obligation to update any forward‐looking statements, except as required by applicable securities laws.

Friday, August 31st, 2012 Uncategorized Comments Off on Brigus Gold (BRD) Completes Sale of Calais Notes

Perceptron (PRCP) Announces the Sale of Its Non-Core Commercial Unit

PLYMOUTH, MI — (Marketwire) — 08/31/12 — Perceptron, Inc. (NASDAQ: PRCP) today announced that, effective August 30, 2012, the Company sold certain assets and liabilities of its Commercial Products Business Unit (“CBU”) to Inspectron, Inc. (“Inspectron”). CBU, one of Perceptron’s two reporting segments, designs and markets products for sale to professional tradespeople in the electrical, mechanics, plumbing, and construction markets. In fiscal year 2012, CBU accounted for approximately 9% of Perceptron’s total sales.

The purchase price was approximately $838,000 in cash. In addition, Perceptron retained CBU’s accounts receivable balance of approximately $608,000 that existed at the time of sale. Inspectron acquired the inventory, tooling, customer contracts, patents, trademarks, and other assets associated with CBU’s business operations. Under the agreement, Inspectron also assumed all of CBU’s service parts and warranty obligations and vendor commitments. Inspectron’s President is Richard Price, former Perceptron Senior Vice President of the Commercial Products Business Unit.

“We are pleased to have completed the sale of CBU and to be able to focus our attention on our Industrial Business Unit (“IBU”)”, said Harry Rittenour, President and CEO of Perceptron. “We considered a wide range of alternatives for CBU over the past several months, including sale, continued operation on a reduced scale, and closure. After a thorough evaluation, management and the board concluded that this sale produced the best outcome for the Company, its shareholders, and CBU’s customers.”

“Looking forward, we will concentrate on our Industrial Business Unit, which accounted for all of Perceptron’s growth and profits, and over 90% of sales in fiscal year 2012,” added Mr. Rittenour. “We are encouraged by the strength of this business over the past year as well as the possibilities that IBU provides us in fiscal year 2013 and beyond.”

Jack Lowry, Perceptron’s Chief Financial Officer, added: “We will be releasing our fiscal year 2012 financial results on Tuesday, September 4, 2012 and our earnings call is scheduled for Wednesday, September 5, 2012 at 10:00 A.M. eastern time. The Company will provide additional information about the sale of CBU during the earnings call. CBU’s financial results will be reported as discontinued operations in fiscal year 2012, and prior years’ results will be presented on a consistent basis.”

About Perceptron®
Perceptron develops, produces, and sells non-contact measurement and inspection solutions for industrial applications. The Company’s products provide solutions for manufacturing process control as well as sensor and software technologies for non-contact measurement, scanning, and inspection applications. Automotive and manufacturing companies throughout the world rely on Perceptron’s metrology solutions to help them manage their complex manufacturing processes to improve quality, shorten product launch times and reduce overall manufacturing costs. The Company also offers Value Added Services such as training and customer support services. Headquartered in Plymouth, Michigan, Perceptron has approximately 220 employees worldwide, with operations in the United States, Germany, France, Spain, Brazil, Japan, Singapore, China and India. For more information, please visit www.perceptron.com.

Safe Harbor Statement
Certain statements in this press release may be “forward-looking statements” within the meaning of the Securities Exchange Act of 1934, including the Company’s expectation as to its fiscal year 2013, and future new order bookings, revenue, expenses, income and backlog levels, trends affecting its future revenue levels, the rate of new orders, the timing of revenue and income from new products which we have recently released or have not yet released, and the timing of the introduction of new products. When we use words such as “will,” “should,” “believes,” “expects,” “anticipates,” “estimates” or similar expressions, we are making forward-looking statements. We claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 for all of our forward-looking statements. While we believe that our forward-looking statements are reasonable, you should not place undue reliance on any such forward-looking statements, which speak only as of the date made. Because these forward-looking statements are based on estimates and assumptions that are subject to significant business, economic and competitive uncertainties, many of which are beyond our control or are subject to change, actual results could be materially different. Factors that might cause such a difference include, without limitation, the risks and uncertainties discussed from time to time in our reports filed with the Securities and Exchange Commission, including those listed in “Item 1A – Risk Factors” of the Company’s Annual Report on Form 10-K for fiscal 2011. Other factors not currently anticipated by management may also materially and adversely affect our financial condition, liquidity or results of operations. Except as required by applicable law, we do not undertake, and expressly disclaim, any obligation to publicly update or alter our statements whether as a result of new information, events or circumstances occurring after the date of this report or otherwise. The Company’s expectations regarding future bookings and revenues are projections developed by the Company based upon information from a number of sources, including, but not limited to, customer data and discussions. These projections are subject to change based upon a wide variety of factors, a number of which are discussed above. Certain of these new orders have been delayed in the past and could be delayed in the future. Because the Company’s products are typically integrated into larger systems or lines, the timing of new orders is dependent on the timing of completion of the overall system or line. In addition, because the Company’s products have shorter lead times than other components and are required later in the process, orders for the Company’s tend to be issued later in the integration process. A significant portion of the Company’s projected revenues and net income depends upon the Company’s ability to successfully develop and introduce new products, expand into new geographic markets and successfully negotiate new sales or supply agreements with new customers. Because a significant portion of the Company’s revenues are denominated in foreign currencies and are translated for financial reporting purposes into U.S. Dollars, the level of the Company’s reported net sales, operating profits and net income are affected by changes in currency exchange rates, principally between the U.S. Dollar and Euro. Currency exchange rates are subject to significant fluctuations, due to a number of factors beyond the control of the Company, including general economic conditions in the United States and other countries. Because the Company’s expectations regarding future revenues, order bookings, backlog and operating results are based upon assumptions as to the levels of such currency exchange rates, actual results could differ materially from the Company’s expectations.

Contact:
Jack Lowry
Vice President of Finance and CFO
734 414-6100

Friday, August 31st, 2012 Uncategorized Comments Off on Perceptron (PRCP) Announces the Sale of Its Non-Core Commercial Unit

Idera Pharmaceuticals (IDRA) to Present at the Rodman & Renshaw Annual Conference

Idera Pharmaceuticals, (NASDAQ: IDRA) a biotechnology company developing Toll-like receptor candidates for the treatment of autoimmune diseases and for use as vaccine adjuvants, today announced that members of the management team will be presenting at the Rodman & Renshaw Annual Global Investment Conference taking place at the Waldorf Astoria in New York City. The presentation will be made in the in North Foyer on Monday, September 10, from 11:15 to 11:40 AM.

A live audio webcast of the presentation will be available in the Investor section of Idera’s website: www.iderapharma.com. An archived version will also be available on the Company’s website after the event for a limited time.

About Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals applies its proprietary Toll-like receptor (TLR) drug discovery platform to create immunomodulatory drug candidates and has clinical development programs in autoimmune diseases. Additionally, Idera has a collaboration with Merck & Co. for the use of TLR-targeted candidates as vaccine adjuvants. The Company is also advancing its gene-silencing oligonucleotide (GSO) technology for the purpose of inhibiting the expression of disease-promoting genes. For more information, visit http://www.iderapharma.com.

Friday, August 31st, 2012 Uncategorized Comments Off on Idera Pharmaceuticals (IDRA) to Present at the Rodman & Renshaw Annual Conference

The Wet Seal, Inc. (WTSLA) Announces August Comparable Store Sales Declined 18.3%

The Wet Seal, Inc. (Nasdaq: WTSLA), a leading specialty retailer to young women, reported net sales and comparable store sales for the four-week period ended August 25, 2012, or fiscal August, as follows:

Fiscal August

Comparable Store Sales

Net Sales
% Change

% Change From

$ in Millions

Last Year

This Year

Last Year
Wet Seal $ 43.6 -15.8 % -18.5 % 7.3 %
Arden B 5.2 -17.0 % -16.3 % -8.7 %
Total $ 48.8 -15.9 % -18.3 % 5.5 %

E-commerce sales rose 0.3% in fiscal August, representing the first increase since April 2011.

The Company today issued the following statement:

“August sales results were in line with our expectations. Since the start of August our aggressive return to our core expertise of fast fashion merchandising has included merchandising to a broader demographic, including the young teen customer, sourcing a wider variety of product more directly from fast fashion vendors, committing to merchandise purchases closer to time of need, and focusing our price points on our core customer – all of which have long driven success at the Company.”

About The Wet Seal, Inc.

Headquartered in Foothill Ranch, California, The Wet Seal, Inc. is a leading specialty retailer of fashionable and contemporary apparel and accessory items. As of August 25, 2012, the Company operated a total of 551 stores in 47 states and Puerto Rico, including 469 Wet Seal stores and 82 Arden B stores. The Company’s products can also be purchased online at www.wetseal.com or www.ardenb.com. For more Company information, visit www.wetsealinc.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements that relate to the intent, belief, plans or expectations of the Company or its management. All forward-looking statements made by the Company involve material risks and uncertainties and are subject to change based on factors beyond the Company’s control. Accordingly, the Company’s future performance and financial results may differ materially from those expressed or implied in any such forward-looking statements. Such factors include, but are not limited to, those described in the Company’s filings with the Securities and Exchange Commission. This news release contains results reflecting partial year data and non-fiscal data that may not be indicative of results for similar future periods or for the full year. The Company will not undertake to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized.

Thursday, August 30th, 2012 Uncategorized Comments Off on The Wet Seal, Inc. (WTSLA) Announces August Comparable Store Sales Declined 18.3%

Sopris Learning (ABCD) 2012 Fall Webinar Series

LONGMONT, Colo., Aug. 30, 2012 /PRNewswire/ — Sopris Learning, a leading provider of evidence-based assessments, supplemental materials, intervention solutions, positive behavior interventions and supports, and professional development offerings, announced today that it will host its fifth seasonal complimentary webinar series focused on ways to improve student outcomes and meet rigorous standards with robust, relevant, real-world solutions and classroom strategies.

The complimentary series is designed to support leaders in implementing proven, practical solutions. Each presentation in the Sopris Learning 2012 Fall Webinar Series connects attendees to authors who will share their cutting-edge research, as well as education consultants and trainers who will provide teaching tips and strategies for a total of more than 18 hours of professional development over the course of the series. Interested educators may register for the webinars starting today at www.soprislearningwebinars.com/fall.

“The continuing Sopris Learning webinar series allows educators nationwide the opportunity to interact directly with leading authors, educational consultants, and creators of outstanding products and professional development programs,” says George Logue, president of Sopris Learning. “The format provides the ability for webinar participants to customize solutions needed for their particular school and classrooms. By providing these complimentary professional development opportunities, teacher support is ongoing and comprehensive.”

New features to this fall series are multipart presentations and updated presentations that incorporate new research reflecting changes in the educational landscape. The series focuses on topics that are of interest to educators, such as implementation of the Common Core State Standards.

Topics feature strategies that can be applied in the classroom immediately following the webinars. Renowned authors and education trainers/consultants who will be featured throughout the webinar series include: Jan Hasbrouck, Ph.D.; Judith Hochman, Ed.D.; Pat Sekel, Ph.D.; Kelly Powell-Smith, Ph.D.; James Martin, Ph.D.; Sandra Jones, Ph.D.; Melody Ilk, M.A.; Stephanie Gottwald, M.A.; Antonio Fierro, Ed.D., and Howard Knoff, Ph.D.

“In this day of information overload and the need to determine what information is most essential for school-based practice, feedback from these webinars has been overwhelmingly positive,” says Dr. Knoff, author and presenter in the past two Sopris Learning webinar series. “Practitioners appreciate that we provide evidence-based but implementation-friendly practices, and that we recognize the importance of presenting systems and strategies that result in solid student, staff, and school outcomes.”

Kathy C. Villere, a speech-language pathologist from Monument, Colorado, commented: “I continually seek new ideas to use with the students I see in private therapy and to share with preschool teachers with whom I consult. Attending the Spring 2012 Sopris Learning Webinar Series enabled me to accomplish both of those goals by listening to language and literacy experts from around the country in the comfort of my own home. I listened to the free sessions live or taped, whichever best suited my schedule. I walked away from each session with a new insight or idea to implement.”

The series will begin Monday, September 17, 2012, and end Monday, November 12, 2012. All webinars start at 11 a.m. ET and are one hour in length to include a live question-and-answer period with the presenter, which is moderated by the host of the series. All webinars are recorded so that those who register may listen to each webinar at their own convenience. Archived recordings will be posted after the conclusion of each webinar at www.soprislearningwebinars.com.

For more information on the Sopris Learning 2012 Fall Webinar Series or to register, visit www.soprislearningwebinars.com/fall.

About Sopris Learning
Sopris Learning is committed to bringing learning to life for students and making professional growth meaningful for educators. We are proud to represent the life’s work of world-renowned researchers and education leaders. For 35 years, Sopris Learning has supported teachers and students with a range of proven assessments, academic interventions, literacy and math supplements, positive behavior supports, and professional development. With a firm commitment to translating research into practice, we have helped schools and districts boost student participation, improve test scores, and increase graduation rates. Sopris Learning is a business unit of Cambium Learning Group, Inc. [Nasdaq: ABCD] based in Dallas, Texas. For more information, please visit www.soprislearning.com.

Media and Investor Contact:
Shannan Overbeck
Cambium Learning Group, Inc.
214.932.9476
shannan.overbeck@cambiumlearning.com

Thursday, August 30th, 2012 Uncategorized Comments Off on Sopris Learning (ABCD) 2012 Fall Webinar Series

Gold Standard (GSV) Confirms Interests Acquired in Pinon Gold Deposit

VANCOUVER, BRITISH COLUMBIA — (Marketwire) — 08/30/12 — Gold Standard Ventures Corp. (TSX VENTURE:GSV)(NYSE MKT:GSV)(NYSE Amex:GSV) (“Gold Standard” or the “Company”) (www.goldstandardv.com) today released additional information on the leases (the “Leases”) entered into with various land holders encompassing approximately 4,128 net mineral acres of land adjacent to the Company’s flagship Railroad gold project in Elko County, Nevada. Acquisition of these Leases was originally announced by Gold Standard in its news release of March 28, 2012.

The Leases grant Gold Standard the exclusive right to explore, mine and develop varying percentage holdings in portions of what the company calls the ‘South Railroad Project’ which includes the Pinon District immediately south of the Railroad District. The Leases grant Gold Standard control of approximately 32% of strategic sections in the Pinon district which the Company estimates give it control of approximately 32% of the historic South Bullion and Trout Creek deposits. Together, these occurrences are known as the Pinon deposit and considerable geologic and exploration data exist for them in recognized peer-reviewed publications. The remaining interests in these lands are held by others including Manhattan Mining Company (“MMC”) on behalf of Royal Standard Minerals Inc. (“RSM”).

For the Trout Creek Deposit, a paper entitled “Geology of the Trout Creek Disseminated Gold Deposit, Elko Co. Nevada” authored by Phillip Jackson and Joseph Ruetz and published in Geology and Ore Deposits of the Great Basin (GSN, 1991. pp.729-734) states that “preliminary geologic reserves are estimated at 150,000 contained ounces of gold and mineralization is open-ended. Gold and silver ratio is about 1:8.” Another paper from the same volume entitled “Geology and Mineralization at the South Bullion Deposit, Pinion Range, Elko Co., Nevada: Implications for Western United States Cenozoic Tectonics” authored by Borden Putnam and Edmund Henriques (pp.713-728) states that “Newmont Exploration Ltd has identified a drill inferred geologic resource exceeding 20 million tons at an average grade of 0.026 oz/st Au, based on 0.01oz/st cutoff, 20 foot minimum bench, and a density of 13 cubic feet per short ton, for a total of 520,000 contained ounces.”

Gold Standard cautions that these historic resource and reserve estimates were derived from data assembled prior to the introduction of National Instrument 43-101. The Company notes that, to its knowledge, a Qualified Person has not completed sufficient work to classify the historical estimate as mineral resources or reserves under National Instrument 43-101 and the available data may not meet the standards required to support such a classification. Gold Standard Ventures is therefore not reporting these historical estimates as current mineral resources or reserves.

Dave Mathewson, Gold Standard`s Vice-President of Exploration, noted that “almost all the mineralized material is oxidized. The alteration and character of the gold mineralization is similar to the Emigrant sediment-hosted gold deposit that Newmont is currently putting into production. In our view, there is potential to expand the known mineralization.”

Gold Standard President and CEO Jonathan Awde stated that “as matters now stand, development of Pinon will have to be undertaken jointly by its owners. We look forward to achieving a mutually beneficial arrangement for all parties to advance the Pinon deposit.”

As previously reported the provisions for all of the Leases are substantially the same and provide for a primary term of 10 years but will continue thereafter as long as commercial mining operations are being conducted on the lands. Each Lease is subject to a small upfront signing bonus and annual advance minimum royalty (“AMR”) payments of US$17.50 per acre in the first and second years, increasing to US$28.00 per acre in the seventh year and thereafter, of which approximately US$125,235.71 has been paid to date. The Leases are also subject to a production royalty of 5% of net smelter returns (payable in proportion to the interest held), against which the AMR payments shall be credited and recouped up to 80%.

GSV now controls approximately 19,764 net mineral acres associated with its Railroad Project.

The scientific and technical content and interpretations contained in this news release have been reviewed, verified and approved by Steven R. Koehler, Gold Standard’s Manager of Projects, BSc. Geology and CPG-10216, a Qualified Person as defined by NI 43-101, Standards of Disclosure for Mineral Projects.

ABOUT GOLD STANDARD VENTURES – Gold Standard is a Canadian-based company focused on the acquisition and exploration of district-scale and other gold-bearing mineral properties exclusively in the State of Nevada, United States. The Company’s flagship property is the Railroad Project, located in Elko County, Nevada. The Railroad Project is a prospective gold exploration target comprising approximately 19,764 acres (30.8 square miles) within the Carlin Trend of north-central Nevada.

On behalf of the Board of Directors of Gold Standard,

Jonathan Awde, President and Director

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. All statements, other than statements of historical fact, included herein including, without limitation, statements about the intended use of proceeds from the Offering are forward looking statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following risks: operational risks associated with mineral exploration; fluctuations in commodity prices; title matters; and the additional risks identified in our filings with Canadian securities regulators on SEDAR in Canada (available at www.sedar.com) and with the SEC on EDGAR (available at www.sec.gov/edgar.shtml). These forward-looking statements are made as of the date hereof and, except as required under applicable securities legislation, the Company does not assume any obligation to update or revise them to reflect new events or circumstances.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the NYSE MKT accepts responsibility for the adequacy or accuracy of this news release.

Contacts:
Gold Standard Ventures Corp.
Jonathan Awde
President
604-669-5702
info@goldstandardv.com
www.goldstandardv.com

Thursday, August 30th, 2012 Uncategorized Comments Off on Gold Standard (GSV) Confirms Interests Acquired in Pinon Gold Deposit

Cardium (CXM) to Present at the Rodman & Renshaw Annual 2012 Healthcare Investment Conference

SAN DIEGO–(BUSINESS WIRE)–

Cardium Therapeutics (NYSE MKT: CXM) today announced that Christopher J. Reinhard, Chairman & CEO will present at the Rodman & Renshaw Annual Healthcare Investment Conference on Monday, September 10, 2012 at 3:15 p.m. Eastern Time. The conference is being held September 9-11, 2012 at the Waldorf-Astoria Hotel in New York City. An audio webcast of the Company’s presentation will be available live and by replay and can be accessed at http://www.wsw.com/webcast/rrshq22/cxm or at the Investors section of Cardium’s website at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-calendar. An updated investor presentation is now available on Cardium’s website at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-presentations.

About Cardium

Cardium is an asset-based health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative products and businesses with the potential to address significant unmet medical needs and having definable pathways to commercialization, partnering or other economic monetizations. Cardium’s current portfolio includes the Tissue Repair Company, Cardium Biologics, and the Company’s in-house MedPodium Health Sciences healthy lifestyle product platform. The Company’s lead commercial product Excellagen® topical gel for wound care management, recently received FDA clearance for marketing and sale in the United States. Cardium’s lead clinical development product candidate Generx® is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease. In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company’s biomedical investment portfolio. News from Cardium is located at www.cardiumthx.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release or the referenced investor presentation are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from expectations. For example, there can be no assurance that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or in actual use; that new clinical studies will be successful or will lead to approvals or clearances from health regulatory authorities, or that approvals in one jurisdiction will help to support studies or approvals elsewhere; that the company can attract suitable commercialization partners for our products or that we or partners can successfully commercialize them; that our product or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive or blocked by third party proprietary rights or other means; that the products and product candidates referred to in this report or in our other reports will be successfully commercialized or will enhance our market value; that new product opportunities or commercialization efforts will be successfully established; that third parties on whom we depend will perform as anticipated; that we can raise sufficient capital from partnering, monetization or other fundraising transactions to maintain our stock exchange listing or adequately fund ongoing operations; or that we will not be adversely affected by these or other risks and uncertainties that could impact our operations, business or other matters, as described in more detail in our filings with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2012 Cardium Therapeutics, Inc. All rights reserved.

For Terms of Use Privacy Policy, please visit www.cardiumthx.com.

Cardium Therapeutics®, Generx®, Cardionovo™, Tissue Repair™, Gene Activated Matrix™, GAM™, Excellagen®, Excellarate™, Osteorate™, MedPodium®, Appexium®, Linée®, Alena®, Cerex®, D-Sorb™, Neo-Energy®, Neo-Carb Bloc®, Neo-Chill™, and Nutra-Apps® are trademarks of Cardium Therapeutics, Inc. or Tissue Repair Company.

Contact:
Cardium Therapeutics, Inc.
Bonnie Ortega
Director, Investor/Public Relations
Tel: (858) 436-1018
Email: InvestorRelations@cardiumthx.com

Thursday, August 30th, 2012 Uncategorized Comments Off on Cardium (CXM) to Present at the Rodman & Renshaw Annual 2012 Healthcare Investment Conference

Empire Resorts/MRMI (NYNY) Signs a Labor Peace Agreement with the New York Hotel

Empire Resorts, Inc.’s (“Empire”) (NASDAQ-GM: NYNY) wholly owned subsidiary, Monticello Raceway Management, Inc. (“MRMI”), and the New York Hotel and Motel Trades Council (“NYHMTC”), the union that represents approximately 100 workers at the Monticello Casino and Raceway, today announced a Labor Peace Agreement (“LPA”) for MRMI’s proposed racetrack, casino and hotel at the site of the former Concord Resort. The parties also announced a new five year Collective Bargaining Agreement (“CBA”) for NYHMTC members employed by MRMI, which includes annual salary increases, sets wages for new hires and addresses employee contributions toward health benefits.

“These agreements are great for existing workers and the entire community,” said Peter Ward, President of NYHMTC. “Empire is not only a strong union partner, but a strong community partner, committed to creating good jobs in a region that desperately needs them. We look forward to supporting them as they seek to create even more good union jobs at the new facility.”

Empire’s CEO Joseph D’Amato said, “We look forward to continuing our good working relationship with strong partners like Peter Ward and the NYHMTC at our current facility. We are simultaneously moving forward with our development plans at the site of the former Concord Resort. In conjunction with Entertainment Properties Trust (NYSE: EPR), this planned family and entertainment destination will create transformative job opportunities for residents of Sullivan County and the Catskills region.”

Empire/MRMI and Entertainment Properties Trust have presented a comprehensive master development plan for 1,500 acres at the site of the former Concord Resort, conceived by the industry-leading architect and master planning firm Hart Howerton. Bringing new energy to a region with rich history, the planned destination resort is expected to include a casino, hotel and harness racetrack (designed by JCJ Architecture, a nationally recognized casino architectural firm), specialty lodging, and championship golf experience, complimented by retail, dining, entertainment and recreational uses, and new residential communities.

The proposed master plan represents a new way of thinking about resort development in the Catskills. The plan envisions a multi-faceted destination resort which will become a catalyst for investment in the region. A place to find adventure or relaxation, it will offer family-centered attractions and amenities surrounded by the natural beauty of the Catskills.

Empire’s Chairman of the Board Emanuel Pearlman concluded, “These agreements with the NYHMTC mark an important milestone as we focus on the future. We are mindful that our project’s progress represents a significant prospect of hundreds of desperately-needed, well-paying jobs with benefits for Sullivan County and the Catskills.”

About the New York Hotel and Motel Trades Council

The New York Hotel and Motel Trades Council is the union of hotel, hospitality and gaming workers in New York. NYHTC represents over 30,000 non-managerial employees working in all hotel departments in over 300 Hotels across New York and New Jersey.

About Empire

Empire Resorts, Inc. owns and operates, through its subsidiary Monticello Raceway Management, Inc., the Monticello Casino and Raceway, a harness racing track and casino located in Monticello, New York, and is 90 miles from midtown Manhattan. For additional information, please visit http://www.empireresorts.com.

Wednesday, August 29th, 2012 Uncategorized Comments Off on Empire Resorts/MRMI (NYNY) Signs a Labor Peace Agreement with the New York Hotel

MEI Pharma (MEIP) CEO To Present At Stifel Nicolaus Healthcare Conference

Live Webcast from Boston on Wednesday, September 5

SAN DIEGO, Aug. 29, 2012 /PRNewswire/ — MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for the treatment of cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present an update on MEI Pharma and its lead oncology drug candidates, ME-143, ME-344 and Pracinostat, at the Stifel Nicolaus Healthcare Conference on Wednesday, September 5, 2012 at 3:50 p.m. Eastern time from the Four Seasons Hotel in Boston. A live webcast of the presentation can be accessed at www.meipharma.com/investor. A replay will be available approximately one hour after the presentation.

(Logo: http://photos.prnewswire.com/prnh/20120628/LA32362LOGO)

About MEI Pharma

MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for the treatment of cancer. The Company’s clinical development pipeline includes two proprietary isoflavone-based drug candidates, ME-143 and ME-344, and a potential best-in-class, oral histone deacetylase (HDAC) inhibitor, Pracinostat.

Results from a Phase I dose-escalation trial of intravenous ME-143 in heavily treated patients with solid refractory tumors were presented at the American Society of Clinical Oncology Annual Meeting in June 2012. The Company received FDA approval of its investigational new drug application for ME-344 in April 2012 and initiated a Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors shortly thereafter. Pracinostat has been tested in more than 150 patients in multiple Phase I and exploratory Phase II clinical trials, including advanced hematologic disorders such as acute myeloid leukemia and myelofibrosis. MEI Pharma owns exclusive worldwide rights to ME-143, ME-344 and Pracinostat. For more information, go to www.meipharma.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management’s current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

SOURCE MEI Pharma, Inc.

Wednesday, August 29th, 2012 Uncategorized Comments Off on MEI Pharma (MEIP) CEO To Present At Stifel Nicolaus Healthcare Conference

China Precision Steel (CPSL) Reverse Stock Split for NASDAQ Bid Price Compliance

SHANGHAI, Aug. 29, 2012 /PRNewswire-Asia/ — China Precision Steel Inc. (Nasdaq: CPSL), a niche precision steel processing company principally engaged in producing and selling high precision cold-rolled steel products, announced today that it effected a reverse split of its common stock at a ratio of 1 share of common stock for every 12 shares. The reverse stock split became effective just prior to market open on Tuesday, August 28, 2012. China Precision Steel’s common stock will continue to be traded on the NASDAQ Capital Market under the symbol “CPSL”. CPSL’s Board of Directors were authorized by CPSL stockholders to effect the reverse split at the annual meeting of stockholders held on June 29, 2012.

As a result of the reverse split, every twelve shares of China Precision Steel’s issued and outstanding common stock was converted automatically into one issued and outstanding share of its common stock without any change in the par value per share or any need to surrender stock certificates. The reverse split will reduce the number of outstanding shares of China Precision Steel’s common stock from approximately 46.6 million shares to approximately 3.9 million shares. Proportional adjustments will be made to the number of shares of China Precision Steel’s common stock issuable upon exercise or conversion of China Precision Steel’s outstanding equity awards, as well as the applicable exercise price.

Mr. Hai Sheng Chen, Chief Executive Officer, stated, “We are effecting this reverse stock split to raise China Precision Steel’s common stock price in order to regain compliance with the NASDAQ Capital Market’s minimum bid price requirement for continued listing. With our bid price compliance addressed we plan to focus our attention on continuing to produce precision steel products for our customers while taking measures to try to improve our operating efficiencies, despite the difficult macro-economic environment.”

About China Precision Steel

China Precision Steel, Inc. is a niche precision steel processing company principally engaged in the production and sale of high precision, cold-rolled steel products and provides value added services such as heat treatment and cutting medium and high carbon, hot-rolled steel strips. China Precision Steel’s high precision, ultra-thin, high strength (7.5 mm to 0.05 mm) cold-rolled steel products are mainly used in the production of automotive components, food packaging materials, saw blades and textile needles. The Company primarily sells to manufacturers in the People’s Republic of China and is expanding into overseas markets such as Nigeria, Thailand, Indonesia and the Philippines. China Precision Steel was incorporated in 2002 and is headquartered in Sheung Wan, Hong Kong. Additional information can be found at the Company’s website http://chinaprecisionsteelinc.com.

Forward-looking Statements

This press release may contain forward-looking statements regarding China Precision Steel, Inc. (the “Company”) within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact included herein are “forward-looking statements” including statements regarding: the ability of the Company to maintain compliance with the NASDAQ Capital Market’s minimum bid price requirement for continued listing; the general ability of the Company to achieve its commercial objectives, including the Company’s plan to implement measures to improve operating efficiencies; the business strategy, plans and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects,” “anticipates,” “seeks,” “should,” “could,” “intends,” or “projects” or similar expressions, involve known and unknown risks and uncertainties. These statements are based upon the Company’s current expectations and speak only as of the date hereof. Any indication of the merits of a claim does not necessarily mean the claim will prevail at trial or otherwise. Financial performance in one fiscal period does not necessarily mean continued or better performance in the future. The Company’s actual results in any endeavor may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties discussed in the Company’s filings at www.sec.gov, which factors or uncertainties may be beyond our ability to foresee or control. You are urged to consider these factors carefully in evaluating the forward-looking statements herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company’s expectations.

Contact Information:

Elite IR
Leslie J. Richardson, Partner
Leslie.richardson@elite-ir.com

Wednesday, August 29th, 2012 Uncategorized Comments Off on China Precision Steel (CPSL) Reverse Stock Split for NASDAQ Bid Price Compliance

Longhai Steel (LGHS) Completes Testing of New Steel Wire Facility

XINGTAI CITY, China, Aug. 29, 2012 /PRNewswire-Asia-FirstCall/ — Longhai Steel Inc. (“Longhai of the Company”) (OTCQB: LGHS), a producer of high-quality steel wire products in the People’s Republic of China, today announced it has completed testing of its initial production of high quality steel wire and the Company expects to ramp production of high quality steel wire to full capacity by the end of 2012.

“We are pleased with the testing results from the initial production at our second facility,” stated Steven Ross, Executive Vice President of Longhai Steel. “We have met or exceeded all of our internal performance metrics and look forward to expanding our customer base and broadening our end market footprint.”

About Longhai Steel Inc.

Longhai Steel is a leading producer of high-quality steel wire in eastern China, with annual capacity of 1.5 million metric tons. Longhai’s wire is manufactured into screws, nails, and wire mesh used for fencing and to reinforce concrete. Longhai recently expanded its production facility to include specialized applications such as steel wire rope, steel strand, steel belted radial tires, and steel welding rod. Demand is based on spending in the construction, automotive and infrastructure industries in China. Company website: www.longhaisteelinc.com.

Safe harbor statement

Certain statements in this news release are forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. These forward-looking statements can be identified by terminology such as “anticipate,” “believe,” “could,” “estimates,” “expect,” “future,” “intends,” “may,” “plans,” “should,” “will,” and similar statements.

The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding China’s economic growth, general industry conditions including local supply and price of wire, environmental risks, Longhai ‘s business or growth strategy, Longhai’s ability to achieve the new facility’s production expectation; Longhai’s ability to develop and produce higher margin products that achieve market acceptance; the success of Longhai ‘s investments, risks, and uncertainties regarding fluctuations in earnings, its ability to sustain its previous levels of profitability including its ability to manage growth, intense competition, wage increases in China, its ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, its ability to successfully complete and integrate potential acquisitions, withdrawal of governmental financial incentives, political instability and regional conflicts, and legal restrictions on raising capital or acquiring companies outside China. Although Longhai believes that its expectations stated in this press release are based on reasonable assumptions, actual results may differ from those projected in the forward-looking statements. Although these expectations and the factors influencing them will likely change, we are under no obligation to inform you if they do. These and additional risks that could affect Longhai’s future operating and financial results are more fully described in its filings with the U.S. Securities and Exchange Commission. These filings are available at www.sec.gov.

Longhai may, from time to time, make additional written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission on forms 10-K, 10-Q, and 8-K, in its annual report to shareholders, in news releases and other written materials, and in oral statements made by its officers, directors, or employees to third parties. Longhai does not undertake to update any forward-looking statements that may be made from time to time by or on its behalf, except as required by law.

Contacts:

Longhai Steel Inc.
Steven Ross (English)
Phone: 949-720-1265
Email: sross@longhaisteelinc.com

Cindy Han (English and Chinese)
Phone: 86-139-3099-8773
Email: dhan2625@163.com

MZ Group – North America
Derek Gradwell, SVP, Natural Resources
Phone: 949-259-4995
Email: dgradwell@mzgroup.us
Web: www.mzgroup.us

Wednesday, August 29th, 2012 Uncategorized Comments Off on Longhai Steel (LGHS) Completes Testing of New Steel Wire Facility

Entropic (ENTR) Reports Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

SAN DIEGO, Aug. 28, 2012 (GLOBE NEWSWIRE) — Entropic Communications, Inc. (Nasdaq:ENTR), a world leader in semiconductor solutions for the connected home, announced today that the Compensation Committee of its Board of Directors approved the grant under its 2012 Inducement Award Plan (the “Plan”) to Mr. Vahid Manian, senior vice president, Global Operations, of a stock option to purchase 225,000 shares of common stock and a restricted stock unit covering 90,000 shares of common stock (the “RSUs”) under the Plan. The stock option and RSUs were granted to Mr. Manian on August 27, 2012, his date of hire. The stock option has an exercise price per share equal to $5.31, the fair market value of Entropic’s common stock on the grant date, and vests over four-years, with 25-percent of the shares subject to the stock option vesting on the one-year anniversary of the vesting commencement date and the remainder of the shares vesting in equal monthly installments over the 36-months thereafter. Of the RSUs awarded to Mr. Manian 50,000 shall vest in equal annual installments over a four-year period from the vesting commencement date, and the remaining 40,000 will vest 50-percent following the one-year anniversary of the vesting commencement date and 50-percent following the second-year anniversary of the vesting commencement date. Vesting for both the stock option and RSUs is subject to Mr. Manian’s continued service relationship with Entropic and each award has a 10-year term and is subject to the terms and conditions of the stock option and RSU agreements pursuant to which they were granted.

These RSUs and stock options were granted as inducements material to Mr. Manian entering into employment with Entropic in accordance with NASDAQ Listing Rule 5635(c)(4).

About Entropic Communications

Entropic Communications, Inc. (Nasdaq:ENTR) is a leading global provider of silicon and software solutions to enable connected home entertainment. The Company transforms how traditional HDTV broadcast and streaming video content is seamlessly, reliably, and securely delivered, processed, and distributed into and throughout the home. Entropic’s next-generation home connectivity and set-top box system-on-a-chip (SoC) solutions enable Pay-TV service providers to offer consumers a more captivating whole-home entertainment experience by delivering new, high-performing ways to connect, engage, and enjoy multimedia content. For more information, visit Entropic at:www.entropic.com.

The Entropic Communications logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4255

CONTACT: Entropic Investor Contact:
Debra Hart
+1 858.768.3852
debra.hart@entropic.com

Entropic Media/Industry Analyst Contact:
Chris Fallon
+1 858.768.3827
chris.fallon@entropic.com

Tuesday, August 28th, 2012 Uncategorized Comments Off on Entropic (ENTR) Reports Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

NovaCopper (NCQ) Files NI 43-101 Technical Report on Ruby Creek Zone

Vancouver, British Columbia–(Newsfile Corp. – August 28, 2012) – NovaCopper Inc. (TSX: NCQ) (NYSE-MKT: NCQ) (“NovaCopper” or “the Company”) has filed a National Instrument 43-101 (“NI 43-101”) resource report (the “Report”) on the Ruby Creek Zone of the Bornite deposit for its Upper Kobuk Mineral Project (“UKMP”) located in the highly prospective Ambler mining district of northwest Alaska. As previously announced by the Company on July 18, 2012, the Report identified Indicated Resources at Ruby Creek of approximately 180 million pounds of copper and Inferred Resources of approximately 885 million pounds of copper. The Report was compiled by Mr. Bruce Davis, FAusIMM, the president of BD Resource Consulting Inc. The Report has been filed on SEDAR and EDGAR and is also available on the Company’s website at www.novacopper.com.

Highlights – At a 0.5% copper cutoff grade, the Ruby Creek Zone contains:

Indicated Resources of 6.8 million tonnes at 1.19% Cu for 178.7 million lbs of contained copper.
Inferred Resources of 47.7 million tonnes of 0.84% Cu for 883.2 million lbs of contained copper.

Table 1. Bornite Deposit – Ruby Creek Zone Resources
Indicated Inferred
Cutoff
%Cu Tonnes
(millions) Grade
% Cu Pounds
(millions) Tonnes
(millions) Grade
% Cu Pounds
(millions)
0.3 9.0 1.00 198.6 74.3 0.68 1113.3
0.5 6.8 1.19 178.7 47.7 0.84 883.2
1.0 2.4 2.03 109.3 11.4 1.31 329.8
1.5 1.0 3.26 71.6 1.9 1.94 82.8
2.0 0.6 4.49 55.0 0.5 2.65 30.3

Base Case is 0.5% Cu cut-off grade

Mineral Resources are not Mineral Reserves and do not have demonstrated economic viability. There is no certainty that all or any part of the Mineral Resources will be converted into Mineral Reserves.

Resources stated as contained within a manually constructed potentially economic resource limiting pit shell using metal price of US$3.00 per lb Cu, mining costs of US$1.50 per tonne, processing costs of US$10.00 per tonne, 100% recoveries and an average pit slope of 45 degrees.

Mineral resource tonnage and contained metal have been rounded to reflect the accuracy of the estimate, and numbers may not add due to rounding.

It is important to note that the Ruby Creek Zone resource estimate does not include any part of the highly prospective South Reef target where the Company has focused its 2012 drilling program. Four diamond drill rigs are currently drilling at South Reef with 16 holes and 11,600 meters drilled to date. The Company expects to start reporting drill results from the South Reef drilling in early September and anticipates that this year’s exploration drilling should provide sufficient data for the preparation of a NI 43-101 compliant resource estimate at the South Reef target in Q1 2013. In addition, roughly 1,700 meters in four holes have also been completed at the Sunshine prospect located 12 kilometers west of the Arctic Volcanogenic Massive Sulfide (“VMS”) deposit. Drill results are also expected to be reported from the drilling at Sunshine in September. The Company has also completed a large-scale ground-based and down-hole IP/Resistivity geophysical program to identify new targets and extend existing targets. This work is currently being compiled.

The Ruby Creek Zone resources are also in addition to the Company’s previously reported resources on the high grade Arctic VMS deposit. See Table 2 below for details.

Table 2. Mineral Resource Statement for the Arctic Deposit, Kobuk, Alaska

Category

Metal Grades

Contained Metal

Zone

Tonnage

Cu

Au

Ag

Zn

Pb

Cu

Au

Ag

Zn

Pb

(kt)

(%)

(g/t)

(g/t)

(%)

(%)

(klb)

(koz)

(koz)

(klb)

(klb)

Indicated

1

5,667

4.50

0.91

63.39

6.15

1.06

562,238

165

11,549

767,839

131,817

2

3,792

4.55

0.52

50.79

6.05

0.97

380,495

63

6,193

505,486

81,223

3

2,448

3.56

0.67

53.69

5.56

0.91

191,960

53

4,226

299,991

49,137

4

7,020

3.57

0.96

65.18

5.68

0.96

552,858

216

14,711

879,669

149,032

11

517

4.16

0.25

32.86

3.32

0.34

47,407

4

546

37,857

3,859

Total

19,445

4.05

0.80

59.55

5.81

0.97

1,734,958

501

37,226

2,490,842

415,068

Inferred

0

1,242

2.16

0.35

4.14

2.19

0.70

59,013

14

165

59,879

19,097

1

2,918

3.82

0.70

53.83

5.53

0.92

245,933

66

5,050

355,508

59,425

2

1,386

4.16

0.39

45.43

5.90

0.79

127,207

18

2,025

180,283

24,114

3

1,177

3.99

0.47

48.45

5.04

0.61

103,633

18

1,833

130,809

15,751

4

4,313

3.18

0.84

55.33

4.88

0.83

302,354

116

7,672

463,893

79,326

11

373

4.25

0.29

33.66

3.30

0.35

34,930

3

404

27,118

2,904

Total

11,409

3.47

0.64

46.75

4.84

0.80

873,070

235

17,149

1,217,489

200,616

Mineral Resources are not Mineral Reserves and do not have demonstrated economic viability. There is no certainty that all or any part of the Mineral Resources will be converted into Mineral Reserves.

Resources stated as contained within potentially economically minable underground shapes above a US$75.00/t NSR cut-off.

NSR calculation is based on assumed metal prices of US$2.50/lb for copper, US$1,000/oz for gold, US$16.00/oz for silver, US$1.00/lb for zinc and US$1.00/lb for lead. A mining cost of US$45.00/t and combined processing and G&A costs of US$31.00 were assumed to form the basis for the resource NSR cut-off determination. Note these metal prices and operating costs may differ from those used for the cash flow model.

Mineral resource tonnage and contained metal have been rounded to reflect the accuracy of the estimate, and numbers may not add due to rounding.

The Ambler mining district hosts world-class VMS deposits containing copper, zinc, lead, gold and silver, and carbonate replacement deposits containing copper, cobalt and silver. It is one of the richest and most-prospective known copper districts located in one of the safest geopolitical jurisdictions in the world.

Mr. Bruce Davis, FAusIMM, the president of BD Resource Consulting Inc. and the author of the Report is an independent “qualified person”, within the meaning of NI 43-101, Standards of Disclosure for Mineral Projects. Scott Petsel, P.Geo. (UKMP Project Manager) is a qualified person as defined by NI 43-101 and has reviewed and accepts responsibility for the technical information contained within this press release.

About NovaCopper

NovaCopper is a base metals exploration company focused on exploring and developing the Ambler mining district – one of the richest and most-prospective copper districts located in one of the safest geopolitical jurisdictions in the world. The Company is focused on continuing to identify high-grade mineralization with additional exploration planned in 2012. Using four drill rigs the Company expects to complete between 15,000 meters to 18,000 meters of diamond core drilling this year. NovaCopper has formed an alliance with NANA, an Alaskan Native Corporation and both companies are committed to developing the Ambler mining district in cooperation with the local communities. Our vision is to develop the Ambler mining district into a premier North American copper producer.

NovaCopper Contact:

Patrick Donnelly
Vice President, Corporate Communications

604-638-8088 or 1-855-638-8088

# # #

Cautionary Note Regarding Forward-Looking Statements

This press release includes certain “forward-looking information” and “forward-looking statements” (collectively “forward-looking statements”) within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, including, without limitation, statements relating the future operating or financial performance of NovaCopper, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “estimates”, “potential”, “possible”, and similar expressions, or statements that events, conditions, or results “will”, “may”, “could”, or “should” occur or be achieved. These forward-looking statements may include statements regarding perceived merit of properties; exploration results and budgets; mineral reserves and resource estimates; work programs; capital expenditures; timelines; strategic plans; completion of transactions; market prices for precious and base metals; or other statements that are not statements of fact. Forward-looking statements involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from NovaCopper’s expectations include the uncertainties involving the need for additional financing to explore and develop properties and availability of financing in the debt and capital markets; uncertainties involved in the interpretation of drilling results and geological tests and the estimation of reserves and resources; the need for cooperation of government agencies and native groups in the development and operation of properties; the need to obtain permits and governmental approvals; risks of construction and mining projects such as accidents, equipment breakdowns, bad weather, non-compliance with environmental and permit requirements, unanticipated variation in geological structures, ore grades or recovery rates; unexpected cost increases, which could include significant increases in estimated capital and operating costs; fluctuations in metal prices and currency exchange rates; and other risk and uncertainties disclosed in NovaGold Resources Inc.’s Management Proxy Circular dated February 27, 2012 for the special meeting of securityholders held to consider the spin-out of NovaCopper Inc. filed with the Canadian securities regulatory authorities, and NovaCopper’s registration statement on Form 40-F filed with the United States Securities and Exchange Commission and in other NovaCopper reports and documents filed with applicable securities regulatory authorities from time to time. NovaCopper’s forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made. NovaCopper assumes no obligation to update the forward-looking statements or beliefs, opinions, projections, or other factors, should they change, except as required by law.

Tuesday, August 28th, 2012 Uncategorized Comments Off on NovaCopper (NCQ) Files NI 43-101 Technical Report on Ruby Creek Zone

Magellan Petroleum (MPET) sale to Stratex Oil & Gas Holdings Under Investigation

SHAREHOLDER ALERT: Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Magellan Petroleum in Connection with the Proposed Sale of the Company to Stratex Oil & Gas Holdings

Levi & Korsinsky is investigating the Board of Directors of Magellan Petroleum (“Magellan” or the “Company”) (NasdaqCM: MPET) for possible breaches of fiduciary duty and other violations of state law in connection with the proposed sale of the Company to Stratex Oil & Gas Holdings (PINK: STTX).

Click here to learn more about the investigation: http://zlk.9nl.com/magellan-petroleum-mpet/, or call: 877-363-5972. There is no cost or obligation to you.

Under the terms of the proposed transaction, Magellan shareholders would receive $2.30 for each share of Magellan stock they own. The proposed transaction has a total approximate value of $124 million. The investigation concerns whether the Board of Directors is engaging in adequate process to review the proposed transaction, and whether the consideration to be paid would be fair and adequate.

If you own common stock in Magellan and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/magellan-petroleum-mpet/.

Levi & Korsinsky is a national firm with offices in New York and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major securities lawsuits and have successfully recovered multimillion-dollar damages awards on behalf of investors. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Tuesday, August 28th, 2012 Uncategorized Comments Off on Magellan Petroleum (MPET) sale to Stratex Oil & Gas Holdings Under Investigation

SEFE (SEFE) Retires 4.5 Million Shares of Common Stock

SEFE, Inc. (OTCBB/OTCQB: SEFE) (the “Company”), a sustainability company engaged in offering innovative, pioneering solutions for the world’s energy needs, today announced that it has retired 4.5 million shares of common stock, resulting in an approximate 8% reduction in the number of common shares issued and outstanding.

The retirement of these shares occurred in connection with a Separation and Release Agreement entered into by the Company and a former director. Immediately following the exchange and retirement of the common shares, the number of common shares issued and outstanding was reduced from 59,583,575 to 55,083,575. The DTC float is now 13,774,000, and the number of authorized shares is 200,000,000.

Don Johnston, CEO of SEFE, stated, “The retirement of these common shares is a very positive step toward improving our Company’s overall capital structure and enhancing value for both new and existing shareholders.”

About SEFE, Inc.

SEFE focuses on pushing the boundaries of what’s possible, embracing innovation and employing the cutting-edge to solve problems, and offering sustainable solutions to a world hungry for invention, direction and leadership. SEFE is technology- and solutions-driven, focusing on developing inventions that provide a real-world impact and true profitability. So, success is measured by both a sustainable return on investment, as well as a project’s sustainability from an environmental perspective.

For more information, visit www.SEFElectric.com.

Forward-Looking Statements

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Tuesday, August 28th, 2012 Uncategorized Comments Off on SEFE (SEFE) Retires 4.5 Million Shares of Common Stock

Savient Pharm (SVNT) to Present at the Rodman & Renshaw 14th Annual Healthcare Conference

EAST BRUNSWICK, N.J., Aug. 27, 2012 /PRNewswire/ — Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Louis Ferrari, Chief Executive Officer and President of Savient, will present at the Rodman & Renshaw 14th Annual Healthcare Conference on Monday, September 10th at 4:30 pm Eastern Time at the Waldorf=Astoria Hotel in New York City.

A live webcast of the presentation can be accessed through the investor relations section of the Company’s website at www.savient.com.  Following the live presentation, a replay of the webcast will be available on the Company’s website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University (“Duke”) and Mountain View Pharmaceuticals, Inc. (“MVP”). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company’s website at www.savient.com.

SVNT – G

Contact:

Mary Coleman

Caitlyn Murphy

Savient Pharmaceuticals, Inc.

Burns McClellan

information@savient.com

cmurphy@burnsmc.com

(732) 418-9300

(212) 213-0006

SOURCE Savient Pharmaceuticals, Inc.

Monday, August 27th, 2012 Uncategorized Comments Off on Savient Pharm (SVNT) to Present at the Rodman & Renshaw 14th Annual Healthcare Conference

Zalicus (ZLCS) Announces FDA Approval of 32mg Dose Strength of EXALGO®

Zalicus Inc. (NASDAQ: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) filed by Mallinckrodt Inc., a subsidiary of Covidien plc, for the 32 mg dose strength of EXALGO® (hydromorphone HCl) Extended-Release Tablets (CII), for the management of moderate to severe pain in opioid-tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.

“More than one hundred million Americans1 suffer from debilitating chronic pain that negatively impacts their quality of life; including their ability to work, attend school and care for their families,” commented Mark H.N. Corrigan, MD, President and CEO of Zalicus. “By providing a variety of tablet strengths of EXALGO, physicians and patients can work together to develop and tailor a treatment regimen that optimally controls their pain.”

The rights to EXALGO were acquired by Mallinckrodt LLC, the pharmaceuticals business of Covidien plc, in June 2009 for $15 million in upfront payments, additional development funding of up to $16 million and a $40 million FDA approval milestone payment. Zalicus receives tiered royalties on net sales of EXALGO by Mallinckrodt.

The FDA approved the three existing doses of EXALGO (8, 12 and 16 mg) in March 2010. Mallinckrodt subsequently submitted the sNDA in January 2012 with post-marketing data to support the original application’s compendium of clinical trials demonstrating safety, efficacy and tolerability. Using OROS® technology, EXALGO provides a steady release of hydromorphone throughout the day once steady-state is achieved after three to four days. Additionally, EXALGO has physical properties that may make it difficult to extract the active ingredient using common forms of physical and chemical tampering, including chewing, crushing and dissolving.

All EXALGO dosage strengths, including the new 32mg tablet which will be available soon, are subject to the recently approved Risk Evaluation and Mitigation Strategy (REMS) program for all long-acting and extended-release opioids. The three primary components of this REMS program are: training for prescribers in the form of continuing medical education (CME) initiatives, which will be available by March 2013; updated medication guides for each opioid and a patient counseling document; and assessment and auditing to ensure the reach and effectiveness of prescriber training.

In order to ensure a smooth transition to the class-wide REMS program, Mallinckrodt will maintain the current EXALGO REMS program web site at www.exalgorems.com and continue to provide important EXALGO prescribing information, with a focus on appropriate patient selection and dosing, to new prescribers.

About Zalicus

Zalicus Inc. (Nasdaq: ZLCS) is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases. Zalicus has a portfolio of proprietary clinical-stage product candidates targeting pain and immuno-inflammatory diseases and have entered into multiple revenue-generating collaborations with large pharmaceutical companies relating to other products, product candidates and drug discovery technologies. Zalicus applies its expertise in the discovery and development of selective ion channel modulators and its combination high throughput screening capabilities to discover innovative therapeutics for itself and its collaborators in the areas of pain, inflammation, oncology and infectious disease. To learn more about Zalicus, please visit www.zalicus.com.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning Zalicus, the product EXALGO and its sales potential. These forward-looking statements about future expectations, plans, objectives and prospects of Zalicus and EXALGO may be identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” “plan” or “could” and similar expressions and involve significant risks, uncertainties and assumptions, including risks related to the commercialization of EXALGO by Covidien and those other risks that can be found in the “Risk Factors” section of Zalicus’ annual report on Form 10-K on file with the Securities and Exchange Commission and the other reports that Zalicus periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Zalicus contemplated by these forward-looking statements. These forward-looking statements reflect management’s current views and Zalicus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law.

EXALGO is a registered trademark of Mallinckrodt LLC.

(c) 2012 Zalicus Inc. All rights reserved.

Monday, August 27th, 2012 Uncategorized Comments Off on Zalicus (ZLCS) Announces FDA Approval of 32mg Dose Strength of EXALGO®

Hipcricket and Spanish Broadcasting System (SBSA) Extend Relationship

Hipcricket® (“Hipcricket”), the one-stop mobile marketing and advertising subsidiary of Augme® Technologies, Inc. (OTCBB: AUGT or “Augme”), and Spanish Broadcasting System (NASDAQ: SBSA) (SBS), the largest publicly traded Hispanic-controlled media and entertainment company in the United States, today announced that the companies have deepened their five-year relationship and will extend mobile marketing and advertising opportunities to three additional radio stations, along with SBS Entertainment’s live concerts and events.

U.S. Hispanic media spending continues to grow faster than general market media every year, topping $7 billion in 2011 (source: Advertising Age). This represents an enormous opportunity for SBS, which recently introduced a 360-degree marketing approach that enables advertisers to reach consumers across TV, radio, Web, social and mobile. By partnering with Hipcricket, SBS can now offer advertisers opportunities to reach Hispanic radio audiences in Los Angeles, San Francisco, Chicago, New York and Miami, as well as at SBS Entertainment’s concerts and events through text-to-screen and other mobile programs that drive engagement. Mobile has emerged as an important aspect of live events, enabling audiences to interact in real-time and brands to engage consumers with information, offers, contests and more. SBS also plans to leverage Hipcricket’s AD LIFE® platform for its upcoming mobile Web and gaming initiatives.

“Hispanics have amassed tremendous buying power in recent years, and mobile presents a significant opportunity for marketers looking to reach them,” said Andrew Polsky, VP of Digital Sales at Spanish Broadcasting System. “By extending our relationship with Hipcricket, we can bring new programs to advertisers looking to have one-to-one conversations with Hispanic consumers, while building a sizeable opt-in listener database that provides remarketing opportunities.”

“Our partnership with Spanish Broadcasting System has been incredibly successful on the radio front, and we are thrilled to build upon that foundation with the addition of new stations and the company’s live events,” said Hipcricket President Ivan Braiker. “SBS audiences are already incredibly engaged with entertainment on their mobile devices and therefore present a perfect target for mobile advertising.”

About Spanish Broadcasting System, Inc.

Spanish Broadcasting System, Inc. is the largest publicly traded Hispanic-controlled media and entertainment company in the United States. SBS owns and/or operates 21 radio stations located in the top U.S. Hispanic markets of New York, Los Angeles, Miami, Chicago, San Francisco and Puerto Rico, airing the Tropical, Mexican Regional, Spanish Adult Contemporary and Hurban format genres. The Company also owns and operates MegaTV, a television operation with over-the-air, cable and satellite distribution and affiliates throughout the U.S. and Puerto Rico. SBS also produces live concerts and events and operates www.LaMusica.com, a bilingual Spanish-English online site providing content related to Latin music, entertainment, news and culture. The Company’s corporate Web site can be accessed at www.spanishbroadcasting.com.

About Hipcricket

Hipcricket, Inc., a wholly-owned subsidiary of Augme Technologies, Inc. (OTC.BB: AUGT), is the one-stop mobile marketing and advertising company that empowers brands, agencies and media properties to engage customers, drive loyalty and increase sales. Hipcricket’s customers connect with consumers across every mobile channel, including SMS, 2D/QR codes, mobile websites, advertising networks, social media and branded apps. Hipcricket’s proven technology, strategic and marketing services and experienced account management teams have provided measurable success to a broad range of national and regional brand-name leaders (e.g., Macy’s, MillerCoors, Nestle, Clear Channel) across an industry-leading 200,000+ campaigns. The company has also created the first comprehensive mobile ad network that taps into the buying power of the mass market with industry-leading capabilities to target customers via location and highly-specific demographic information across SMS, display, rich media and video.

Hipcricket is based in New York, with operations in Seattle, Dallas, Chicago, Atlanta, Los Angeles, San Francisco and Miami.

Monday, August 27th, 2012 Uncategorized Comments Off on Hipcricket and Spanish Broadcasting System (SBSA) Extend Relationship

Neuralstem (CUR) Completes Phase I ALS Stem Cell Trial

ROCKVILLE, Md., Aug. 27, 2012 /PRNewswire/ — Neuralstem, Inc. (NYSE MKT: CUR) announced the completion of the Phase I trial of its NSI-566 spinal cord neural stem cells for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), with the eighteenth patient treated. This patient, the third to return to the trial for an additional set of injections, is also the last in the Phase I portion of the trial as it is currently designed, which is scheduled to conclude six months after this final surgery.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

“We are delighted to have completed Phase I in this groundbreaking trial, the first approved by the FDA to test neural stem cells in patients with ALS,” said Karl Johe, PhD, Chairman of Neuralstem’s Board of Directors and Chief Scientific Officer.

“There have been many firsts in this trial, including the first lumbar intraspinal injections, the first cervical region intraspinal injections, and the first cohort of patients to receive both,” said Jonathan D. Glass, MD, Director of the Emory ALS Center. “This has required incredible effort from the Emory medical and support team and I wish to express my thanks to all of them, as well as to acknowledge the generosity and courage of the patients and their families.”

“We have found the procedure to be extremely safe,” said Eva Feldman, MD, PhD, Director of the A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan Health System. “In some patients, it appears that the disease is no longer progressing, but it is too early to know if the result from that small number of patients is meaningful.” Dr. Feldman is the principal investigator (PI) of the trial and an unpaid consultant to Neuralstem.

About the Trial

The Phase I trial to assess the safety of Neuralstem’s NSI-566 spinal cord neural stem cells and intraspinal transplantation method in ALS patients has been underway since January 2010. The trial was designed to enroll up to 18 patients, the last of which was just treated. The first 12 patients were each transplanted in the lumbar (lower back) region of the spine, beginning with non-ambulatory and advancing to ambulatory cohorts.

The trial then advanced to transplantation in the cervical (upper back) region of the spine. The first cohort of three was treated in the cervical region only. The last cohort of three received injections in both the cervical and lumbar regions of the spinal cord. In an amendment to the trial design, The Food and Drug Administration (FDA) approved the return of previously treated patients to this cohort.  The entire 18-patient trial concludes six months after the final surgery.

About Neuralstem

Neuralstem’s patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig’s disease, and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia and chronic stroke. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain’s capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions.  The company is in a Phase Ib safety trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include chronic traumatic encephalopathy (CTE), Alzheimer’s disease, and post-traumatic stress disorder (PTSD).

For more information, please visit www.neuralstem.com or connect with us on Twitter and Facebook.

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem’s technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem’s periodic reports, including the annual report on Form 10-K for the year ended December 31, 2011 and the quarterly report on Form 10-Q for the period ended June 30, 2012.

SOURCE Neuralstem, Inc.

Monday, August 27th, 2012 Uncategorized Comments Off on Neuralstem (CUR) Completes Phase I ALS Stem Cell Trial